146 related articles for article (PubMed ID: 16210035)
1. Role of tyrosine kinases and phosphatases in polycythemia vera.
Zhao ZJ; Vainchenker W; Krantz SB; Casadevall N; Constantinescu SN
Semin Hematol; 2005 Oct; 42(4):221-9. PubMed ID: 16210035
[TBL] [Abstract][Full Text] [Related]
2. Polycythemia vera: scientific advances and current practice.
Tefferi A; Spivak JL
Semin Hematol; 2005 Oct; 42(4):206-20. PubMed ID: 16210034
[TBL] [Abstract][Full Text] [Related]
3. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia.
Bellucci S; Michiels JJ
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):381-98. PubMed ID: 16810614
[TBL] [Abstract][Full Text] [Related]
4. A gain-of-function mutation of JAK2 in myeloproliferative disorders.
Kralovics R; Passamonti F; Buser AS; Teo SS; Tiedt R; Passweg JR; Tichelli A; Cazzola M; Skoda RC
N Engl J Med; 2005 Apr; 352(17):1779-90. PubMed ID: 15858187
[TBL] [Abstract][Full Text] [Related]
5. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.
Baxter EJ; Scott LM; Campbell PJ; East C; Fourouclas N; Swanton S; Vassiliou GS; Bench AJ; Boyd EM; Curtin N; Scott MA; Erber WN; Green AR;
Lancet; 2005 Mar 19-25; 365(9464):1054-61. PubMed ID: 15781101
[TBL] [Abstract][Full Text] [Related]
6. [Acquired mutation of JAK2 tyrosine kinase and polycythaemia vera].
Pargade V; Darnige L; Gaussem P
Ann Biol Clin (Paris); 2006; 64(1):3-9. PubMed ID: 16420986
[TBL] [Abstract][Full Text] [Related]
7. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.
James C; Ugo V; Le Couédic JP; Staerk J; Delhommeau F; Lacout C; Garçon L; Raslova H; Berger R; Bennaceur-Griscelli A; Villeval JL; Constantinescu SN; Casadevall N; Vainchenker W
Nature; 2005 Apr; 434(7037):1144-8. PubMed ID: 15793561
[TBL] [Abstract][Full Text] [Related]
8. [Mutation of protein kinase JAK2 in polycythemia vera: new perspectives in physiopathology and therapy].
Marie I; Hervé F
Rev Med Interne; 2006 Jun; 27(6):473-7. PubMed ID: 16631280
[TBL] [Abstract][Full Text] [Related]
9. A unique activating mutation in JAK2 (V617F) is at the origin of polycythemia vera and allows a new classification of myeloproliferative diseases.
Vainchenker W; Constantinescu SN
Hematology Am Soc Hematol Educ Program; 2005; ():195-200. PubMed ID: 16304380
[TBL] [Abstract][Full Text] [Related]
10. Identification of an acquired JAK2 mutation in polycythemia vera.
Zhao R; Xing S; Li Z; Fu X; Li Q; Krantz SB; Zhao ZJ
J Biol Chem; 2005 Jun; 280(24):22788-92. PubMed ID: 15863514
[TBL] [Abstract][Full Text] [Related]
11. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
[TBL] [Abstract][Full Text] [Related]
12. Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F.
Zaleskas VM; Krause DS; Lazarides K; Patel N; Hu Y; Li S; Van Etten RA
PLoS One; 2006 Dec; 1(1):e18. PubMed ID: 17183644
[TBL] [Abstract][Full Text] [Related]
13. JAKing up hematopoietic proliferation.
Shannon K; Van Etten RA
Cancer Cell; 2005 Apr; 7(4):291-3. PubMed ID: 15837617
[TBL] [Abstract][Full Text] [Related]
14. New insights into the pathogenesis of JAK2 V617F-positive myeloproliferative disorders and consequences for the management of patients.
Villeval JL; James C; Pisani DF; Casadevall N; Vainchenker W
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):341-51. PubMed ID: 16810610
[TBL] [Abstract][Full Text] [Related]
15. The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders.
Michiels JJ; De Raeve H; Berneman Z; Van Bockstaele D; Hebeda K; Lam K; Schroyens W
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):307-40. PubMed ID: 16810609
[TBL] [Abstract][Full Text] [Related]
16. Polycythemia vera and its molecular basis: an update.
Chen G; Prchal JT
Best Pract Res Clin Haematol; 2006; 19(3):387-97. PubMed ID: 16781479
[TBL] [Abstract][Full Text] [Related]
17. [New molecular markers within the chronic myeloproliferative disorders. II: the JAK2 mutation].
Larsen TS; Pallisgaard N; Christensen JH; Gram-Hansen P; Kerndrup GB; Møller MB; Hasselbalch HC
Ugeskr Laeger; 2006 Sep; 168(39):3299-303. PubMed ID: 17032592
[TBL] [Abstract][Full Text] [Related]
18. The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation.
Jamieson CH; Gotlib J; Durocher JA; Chao MP; Mariappan MR; Lay M; Jones C; Zehnder JL; Lilleberg SL; Weissman IL
Proc Natl Acad Sci U S A; 2006 Apr; 103(16):6224-9. PubMed ID: 16603627
[TBL] [Abstract][Full Text] [Related]
19. JAK2 mutations in myeloproliferative disorders.
Tefferi A; Lasho TL; Gilliland G
N Engl J Med; 2005 Sep; 353(13):1416-7; author reply 1416-7. PubMed ID: 16192494
[No Abstract] [Full Text] [Related]
20. [A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera].
Ugo V; James C; Vainchenker W
Med Sci (Paris); 2005; 21(6-7):669-70. PubMed ID: 15985214
[No Abstract] [Full Text] [Related]
[Next] [New Search]
